MecSense AS is a private limited Norwegian start-up company established in 2011 and is headquartered in Oslo. Founder-member Olav Ellingsen currently holds the post of Chairman and CEO in the company. Read more >>
Limitations of Current BGM System
Blood glucose monitoring meters or other systems have been one of the most important trailblazing discoveries in the management of different types of diabetes. This is since the discovery of insulin changed the clinical mode of controlling the disease Read more >>
The invention is related to a sensor for continuous detection of minute change of density in fluids, solids and semisolid bodies by a transducer. The technology is protected with two patent applications Read more >>
The Global SMBG Market
Increasing Popularity of Less Invasive Glucose Monitoring Devices
The global self-monitoring blood glucose (SMBG) devices market accounted for $11,171.1 million in 2014, and it is expected to grow with a CAGR of 5.7% during 2015-2022. Read more >>
Proof of Principle
Diabetes and glucose monitoring: a challenging and growing market...
What is the ideal device?
- The sensor needs to be non-invasive and continuous.
- The sensor needs to be accurate and meet the gold standard for measurements required today for standard invasive glucose sensors (ISO 15197) after calibration. Read more>>
- A non-invasive continuous glucose monitoring device.
- Ease of use: Management focused on ’plug and play’. Rad more>>
The Science Behind the MecSense Non-Invasive Glucose Indicator
MecSense is the first to develop a reliable and economical system for blood CGM Indication in a completely non-invasive manner. The equipment has two important components – a sensor for detecting the blood glucose level and software which converts the signals into glucose readings on a receiving device. The sensor is embedded in the skin patch. Read more >>
The Project is supported with NOK 11 million in public grants from:
Continuous monitoring of:
Dehydration in humans. The density and viscosity of oil. Numerous other applications are under evaluation including medical diagnostics and other industrial applications.